Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Common Equity (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Common Equity for 14 consecutive years, with $126.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 13.21% year-over-year to $126.6 million, compared with a TTM value of $126.6 million through Dec 2025, up 13.21%, and an annual FY2025 reading of $64.7 million, down 49.76% over the prior year.
  • Common Equity was $126.6 million for Q4 2025 at Enanta Pharmaceuticals, up from $64.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $436.0 million in Q1 2021 and bottomed at $64.7 million in Q3 2025.
  • Average Common Equity over 5 years is $239.6 million, with a median of $227.3 million recorded in 2023.
  • Peak annual rise in Common Equity hit 13.21% in 2025, while the deepest fall reached 49.76% in 2025.
  • Year by year, Common Equity stood at $384.4 million in 2021, then fell by 21.74% to $300.8 million in 2022, then tumbled by 36.22% to $191.9 million in 2023, then crashed by 41.73% to $111.8 million in 2024, then rose by 13.21% to $126.6 million in 2025.
  • Business Quant data shows Common Equity for ENTA at $126.6 million in Q4 2025, $64.7 million in Q3 2025, and $79.3 million in Q2 2025.